A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus

Journal of Genetic Engineering and Biotechnology

Table 5 Diagnostic power of IL6 to discriminate patients with HCC from patients with cirrhosis in different three staging systems

Classification	AUC	Sens%	Spe%	PPV%	NPV%	AC%
Number of nodules (n, %)
Single (67, 43.2%)	0.82	78	70	44	91	72
Multiple (88, 56.8)	0.82	78	70	67	81	74
Macrovascular invasion (n, %)
Absent (141, 91%)	0.81	77	70	67	78	73
Present (14, 9%)	0.85	83	70	36	96	72
Size of nodules (n, %)
<2 (48, 31%)	0.82	78	70	44	91	72
>2 (107, 69%)	0.82	78	70	67	81	74
BCLC stage (n, %)
0-A (109, 70.3%)	0.77	71	70	63	78	71
B (46, 29.7)	0.91	91	70	53	96	76
CLIP stage (n, %)
0-1 (122, 79%)	0.78	75	70	67	78	72
2-3 (33, 21%)	0.95	88	70	44	96	74
Okuda stage (n, %)
Stage I (117, 75.5%)	0.79	77	70	65	81	73
Stage II (38, 24.5%)	0.88	80	70	47	85	73